| Sunitinib for the management of advanced renal cell carcinoma. | |
| | |
MedLine Citation:
|
PMID: 20214511 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Targeted agents, such as sunitinib (SUTENT((R))) have become central to the management of advanced and/or metastatic renal cell carcinoma (mRCC). Sunitinib is an oral, multitargeted receptor tyrosine kinase inhibitor that has demonstrated efficacy for the treatment of mRCC in multiple clinical trials. In a Phase III trial in previously untreated patients with mRCC, sunitinib was associated with median progression-free survival of 11 months, which was more than double that observed with interferon-alpha (5 months; p < 0.001). As a result, sunitinib is recommended in international treatment guidelines and is considered a reference standard of care in the first-line setting for patients at favorable or intermediate prognostic risk. Sunitinib is generally well tolerated with a predictable adverse-event profile; the majority of adverse events can be managed with standard medical intervention. This paper presents an overview of data supporting the use of sunitinib for mRCC, and considers the optimal management of sunitinib in clinical practice. |
| | |
Authors:
|
Bernard Escudier |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Expert review of anticancer therapy Volume: 10 ISSN: 1744-8328 ISO Abbreviation: Expert Rev Anticancer Ther Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-03-10 Completed Date: 2010-06-16 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101123358 Medline TA: Expert Rev Anticancer Ther Country: England |
Other Details:
|
Languages: eng Pagination: 305-17 Citation Subset: IM |
Affiliation:
|
Institut Gustave Roussy, 39 Rue Camille Desmoulins, 94805 Villejuif, France. escudier@igr.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
adverse effects,
pharmacology,
therapeutic use* Carcinoma, Renal Cell / drug therapy*, mortality, physiopathology Clinical Trials, Phase III as Topic Disease-Free Survival Drug Delivery Systems Humans Indoles / adverse effects, pharmacology*, therapeutic use Kidney Neoplasms / drug therapy*, physiopathology Neoplasm Metastasis Practice Guidelines as Topic Pyrroles / adverse effects, pharmacology*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Indoles; 0/Pyrroles; 0/sunitinib |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Moderate hypothermia suppressed excessive generation of superoxide anion radical and inflammatory re...
Next Document: AACR-NCI-EORTC International Conference 2009.